Bluebird Bio Financial Statements (BLUE)
|
|
|
|
Report date
|
|
|
23.02.2021 |
04.03.2022 |
29.03.2023 |
13.09.2024 |
27.03.2025 |
|
14.05.2025 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
250.7 |
3.66 |
3.60 |
29.5 |
83.8 |
|
103.9 |
|
Operating Income, bln rub |
|
|
-559.3 |
-590.9 |
-250.2 |
-244.3 |
-270.5 |
|
-216.4 |
|
EBITDA, bln rub |
? |
|
-553.6 |
-556.9 |
-215.6 |
-167.2 |
-156.8 |
|
-115.8 |
|
Net profit, bln rub |
? |
|
-618.7 |
-819.4 |
-230.3 |
-211.9 |
-240.7 |
|
-200.0 |
|
|
OCF, bln rub |
? |
|
-470.4 |
-635.6 |
-353.0 |
-235.0 |
-260.0 |
|
-228.8 |
|
CAPEX, bln rub |
? |
|
29.0 |
23.0 |
13.2 |
9.06 |
2.60 |
|
1.68 |
|
FCF, bln rub |
? |
|
-499.3 |
-658.6 |
-366.2 |
-244.1 |
-262.6 |
|
-230.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
|
|
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
874.9 |
555.7 |
243.7 |
240.2 |
264.9 |
|
244.6 |
|
Cost of production, bln rub |
|
|
5.40 |
38.9 |
10.1 |
33.5 |
89.4 |
|
75.8 |
|
R&D, bln rub |
|
|
319.3 |
319.9 |
240.8 |
167.7 |
94.3 |
|
86.9 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
6.32 |
16.4 |
22.6 |
|
22.7 |
|
|
Assets, bln rub |
|
|
1 781 |
593.8 |
554.9 |
619.2 |
460.2 |
|
296.0 |
|
Net Assets, bln rub |
? |
|
1 355 |
374.3 |
196.3 |
194.5 |
-31.5 |
|
-57.9 |
|
Debt, bln rub |
|
|
90.4 |
89.6 |
367.1 |
330.3 |
358.2 |
|
188.1 |
|
Cash, bln rub |
|
|
680.2 |
299.5 |
180.3 |
221.8 |
62.3 |
|
78.7 |
|
Net debt, bln rub |
|
|
-589.8 |
-209.9 |
186.7 |
108.6 |
295.9 |
|
109.4 |
|
|
Ordinary share price, rub |
|
|
560.2 |
199.8 |
|
|
8.34 |
|
4.97 |
|
Number of ordinary shares, mln |
|
|
62.2 |
68.9 |
78.6 |
71.3 |
9.69 |
|
9.75 |
|
|
Market cap, bln rub |
|
|
34 833 |
13 768 |
0 |
0 |
81 |
|
48 |
|
EV, bln rub |
? |
|
34 244 |
13 558 |
187 |
109 |
377 |
|
158 |
|
Book value, bln rub |
|
|
1 332 |
369 |
186 |
178 |
-47 |
|
-73 |
|
|
EPS, rub |
? |
|
-9.95 |
-11.9 |
-2.93 |
-2.97 |
-24.8 |
|
-20.5 |
|
FCF/share, rub |
|
|
-8.03 |
-9.56 |
-4.66 |
-3.42 |
-27.1 |
|
-23.6 |
|
BV/share, rub |
|
|
21.4 |
5.35 |
2.36 |
2.50 |
-4.82 |
|
-7.47 |
|
|
EBITDA margin, % |
? |
|
-220.8% |
-15 208% |
-5 993% |
-566.7% |
-187.1% |
|
-111.4% |
|
Net margin, % |
? |
|
-246.8% |
-22 375% |
-6 404% |
-718.4% |
-287.2% |
|
-192.4% |
|
FCF yield, % |
? |
|
-1.43% |
-4.78% |
|
|
-325.0% |
|
-475.6% |
|
ROE, % |
? |
|
-45.7% |
-218.9% |
-117.3% |
-108.9% |
763.4% |
|
345.6% |
|
ROA, % |
? |
|
-34.7% |
-138.0% |
-41.5% |
-34.2% |
-52.3% |
|
-67.6% |
|
|
P/E |
? |
|
-56.3 |
-16.8 |
0.00 |
0.00 |
-0.34 |
|
-0.24 |
|
P/FCF |
|
|
-69.8 |
-20.9 |
0.00 |
0.00 |
-0.31 |
|
-0.21 |
|
P/S |
? |
|
138.9 |
3 760 |
0.00 |
0.00 |
0.96 |
|
0.47 |
|
P/BV |
? |
|
26.2 |
37.3 |
0.00 |
0.00 |
-1.73 |
|
-0.67 |
|
EV/EBITDA |
? |
|
-61.9 |
-24.3 |
-0.87 |
-0.65 |
-2.40 |
|
-1.36 |
|
Debt/EBITDA |
|
|
1.07 |
0.38 |
-0.87 |
-0.65 |
-1.89 |
|
-0.94 |
|
|
R&D/CAPEX, % |
|
|
1 102% |
1 391% |
1 823% |
1 851% |
3 626% |
|
5 163% |
|
|
CAPEX/Revenue, % |
|
|
11.6% |
628.2% |
367.2% |
30.7% |
3.10% |
|
1.62% |
|
| Bluebird Bio shareholders |
